Allergan Inc. (AGN) is in the Pharma Industry

• Sort by

• Allergan's Jeffrey L. Edwards Named Orange County CFO of the Year by NIRI Orange County and UCI Extension

  Advanced Medical Optics' CFO Randy Meier is First Recipient of the Thomas A. Klemens Achievement Award

  Research articles 2006-12-08

  Tags: Allergan Inc., Orange PCS

• Botox Challenger Being Bought in $2.8B Cosmetic Deal

  Panic Doesn't Stray Far With New Company's Logo; Ista Gets Regulatory Nod for Xibrom Drug HEALTHCARE Inamed Corp., developer of a potential rival to Allergan Inc.'s Botox wrinkle-fighting drug, is being bought in a big cosmetic surgery deal. Medicis Pharmaceutical Corp. of Scottsdale said last month...

  Research articles 2005-04-04

  Tags: Allergan Inc., Benefits, Government, HEALTHCARE, Mellon Financial Corp., Orange PCS, SALES, SOFTWARE

• The Orange County Register, Calif., Business Briefs Column.

  The Orange County Register, Calif. Knight Ridder/Tribune Business News Feb. 13--FTC ENDS PROBE INTO PATENT OF ALLERGAN'S ACULAR: Irvine-based Allergan Inc., the maker of Botox anti-wrinkle treatments, said the U.S. Federal Trade Commission has closed its investigation into whether the company...

  Research articles 2004-02-13

  Tags: Allergan Inc., FINANCE, FTC, Orange PCS, Raining Data Corp., Valeant Pharmaceuticals International

• Drug Maker Allergan Is Largest Publicly Traded Firm in Orange County, Calif.

  By James B. Kelleher, The Orange County Register, Calif. Knight Ridder/Tribune Business News By James B. Kelleher, The Orange County Register, Calif. Knight Ridder/Tribune Business News

  Research articles 2001-03-08

  Tags: Allergan Inc., Orange PCS

• Former Executive Sues Allergan over Forced Resignation.(Originated from The Orange County Register, Calif.)

  Jul. 31--A lawyer for a former Allergan executive told a jury the Irvine eye-care products maker should pay his client $1.8 million for lost income and for the pain and suffering of being forced to resign. Jul. 31--A lawyer for a former Allergan executive told a jury...

  Research articles 1996-07-31

  Tags: Allergan Inc., Orange PCS

• California's Allergan Inc. Challenges Motive in Employee's Lawsuit.(Originated from The Orange County Register, Calif.)

  A lawyer for Allergan Inc. on Wednesday portrayed a former employee, who has accused the Irvine maker of eye-care products of knowingly selling an unsafe product, as more concerned about suing the company than protecting the public. A lawyer for Allergan Inc. on Wednesday portrayed a...

  Research articles 1996-07-04

  Tags: Allergan Inc., Orange PCS

• Allergan Inc. May Face Fines Over Export of Botox Medicine.(Originated from The Orange County Register, Calif.)

  IRVINE, Calif.--Apr. 18--Allergan Inc. may face civil penalties for exporting a medicine made from the botulism toxin, the company has told investors. But Allergan said it will not face criminal charges in its long-running dispute with the U.S. Commerce Department over Botox, a medicine used...

  Research articles 1996-04-18

  Tags: Allergan Inc., FINANCE, Orange PCS, SOFTWARE, U.S. Department of Commerce

• California-based Allergan's Chairman Keeps Eye on Health-care Reform. (Originated from The Orange County Register, Calif.)

  Mar. 27--An era ends this week at Allergan Inc. in Irvine. Sort of. After 44 years with the pharmaceuticals company he helped found, Gavin S. Herbert officially retires as an Allergan executive and employee. Mar. 27--An era ends this week at Allergan Inc. in Irvine. Sort of....

  Research articles 1994-03-27

  Tags: Allergan Inc., health care, Orange PCS

Additional Resources

• Spectrum Pharmaceuticals Announces Third Quarter Corporate Update and Pipeline Review

  * Approximately $90 Million in Cash and Equivalents as of November 6, 2008 * Signed Collaboration Agreement With Allergan, Inc. for Apaziquone (EOquin([R])) on October 28, 2008 * FUSILEV[TM] Supplemental NDA for Colorectal Cancer Filed October 30, 2008 * Received Unique, Product-Specific J-Code for...

  Articles 2008-11-07

• Spectrum Pharmaceuticals Announces Receipt of $41.5 Million from Allergan, Inc. Per Collaboration Agreement for Apaziquone Announced on October 29th

  * Spectrum Will Receive Up To An Additional $304 Million Based On Achievement Of Certain Clinical, Regulatory And Commercialization Milestones * Spectrum Will Continue to Conduct Clinical Trials * Allergan to Fund 65% of Costs Starting January 1, 2009 IRVINE, Calif. -- Spectrum Pharmaceuticals,...

  Articles 2008-11-06

• Zacks Analyst Blog Highlights: Cabela's Inc., Sanmina-SCI Corp., Dollar Financial Corp., Inspire Pharmaceuticals, Inc. and Allergan, Inc

  CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Cabela's Inc. (NYSE: CAB), Sanmina-SCI Corp. (Nasdaq: SANM), Dollar Financial Corp....

  Articles 2008-11-05

• Polyphor to Enter into an Exclusive Agreement with Allergan for the Development of Protein Epitope Mimetics Inhibitors for Ophthalmology

  Novel Cytokine Inhibitors to Treat Conditions and Diseases Affecting the Eye ALLSCHWIL, Switzerland -- Polyphor Ltd today announced that it has entered into an exclusive worldwide discovery and license agreement with Allergan, Inc., under which Allergan obtains the rights to develop PEM cytokine inhibitors for the treatment of...

  Articles 2008-10-31

• Allergan Reports Third Quarter 2008 Operating Results

  * Board of Directors Declares Third Quarter Dividend IRVINE, Calif. -- Allergan, Inc. (NYSE:AGN) today announced operating results for the quarter ended September 30, 2008. Allergan also announced that its Board of Directors has declared a third quarter dividend of $0.05 per share, payable on December 1, 2008...

  Articles 2008-10-29

• Allergan, Inc. and Spectrum Pharmaceuticals, Inc. Announce Collaboration Agreement for Apaziquone

  * Apaziquone is Currently Being Investigated for the Treatment of Non-Muscle Invasive Bladder Cancer * Spectrum to Receive $41.5 Million at Closing and up to $304 Million in Milestone Payments * Spectrum to Share Profits and Expenses Equally in the United States and Receive Royalties on...

  Articles 2008-10-29

• Sight loss drug to be licensed as cosmetic

  Glaucoma treatment gives users longer eyelashes It started out as a medicine, a prosaic treatment for glaucoma. Now it is being used for its cosmetic effects, promising to turn women into doe-eyed beauties within days. The drug firm Allergan - the 1.5bn global...

  Articles 2008-10-26

• BAROnova Secures Investment From Allergan, Inc

  New Obesity Intervention Device Moving to New Clinical Trials; Has the Potential to Be Safer and More Cost Effective Without Surgery GOLETA, Calif. -- BAROnova, Inc. announced today the closing of its Series B financing of $7.5 million, led by a strategic investment from Allergan, Inc., a global...

  Articles 2008-10-23

• Allergan, Inc. and Clinique Announce Nationwide Availability of CLINIQUE MEDICAL

  - New Skin Care System Satisfies Unmet Need for Product Line Specifically Formulated to Help Support Skin Before and After In-Office Non-Surgical Cosmetic Procedures - IRVINE, Calif. & NEW YORK -- Allergan, Inc. (NYSE:AGN), the #1 global medical aesthetics company, and Clinique, the #1 prestige cosmetics brand in...

  Articles 2008-10-15

• Inspire Announces Issuance of Patent for Elestat®

  DURHAM, N.C. -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that the U.S. Patent and Trademark Office has issued a method of treatment patent related to Elestat([R]) epinastine HCl ophthalmic solution 0.05% for allergic conjunctivitis. This patent, U.S. Patent No. 7,429,602, entitled "Treating Conjunctivitis by Administering an Epinastine Solution to...

  Articles 2008-10-15

• Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol™

  TAMPA, Fla., Oct. 14 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today preliminary results from a pivotal anterior uveitis trial that compared DurezolTM difluprednate ophthalmic emulsion 0.05% dosed four times daily QID to Pred ForteR prednisolone acetate ophthalmic suspension 1%, dosed eight times daily....

  Articles 2008-10-14

• Zacks Analyst Blog Highlights: AutoNation, Inc., Oscient Pharmaceuticals Corp., Equity Residential, ACADIA Pharmaceuticals Inc. and Allergan, Inc

  CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AutoNation, Inc. (NYSE: AN), Oscient Pharmaceuticals Corp. (Nasdaq: OSCI), Equity Residential...

  Articles 2008-10-03